Skip to main content

Published locations for Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis

User login

  • Reset your password
  • /content/alzheimers-anti-tau-drug-fails-phase-iii-posts-some-benefit-monotherapy-subanalysis
  • /familypracticenews/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii
  • /internalmedicinenews/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii
  • /psychiatry/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii-posts-some
  • /internalmedicine/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii-posts
  • /neurology/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii-posts-some
  • /familymedicine/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii-posts
  • /clinicalneurologynews/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii
  • /clinicalpsychiatrynews/article/110885/alzheimers-cognition/alzheimers-anti-tau-drug-fails-phase-iii